Piper Sandler Initiates OKYO at Overweight – $7 Target Highlights Urcosimod's Strong Early Data and Clean Safety Profile
Piper Sandler starts coverage on OKYO Pharma with an Overweight rating and $7 target. Analyst likes lead drug Urcosimod for eye pain with no current treatments.